Clinical trial · Interventional
Patient's Derived Organoids for Drug Screening in Glioblastoma
Development and Characterization of Patient's Derived Organoids as a Platform for the Screening of Novel Therapeutic Treatments for Glioblastoma Multiforme
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study will enroll patients suffering from glioblastoma, a malignant brain tumor. Intervention is intended as a laboratory intervention and not as a clinical intervention. In fact, tumor removed from patients' brains will be sent to a dedicated laboratory to obtain an "avatar" of the tumor, named patient-derived organoid (PDO). A number of experimental antitumor approaches will be studied on PDOs. Results of these experiments will be correlated to the prognosis of patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
| Glioblastoma Multiforme, Adult | Adult Glioblastoma | ALIAS | 0.90 |
| Glioblastoma Multiforme (GBM) | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Development and characterization of PDOs | Biological | — | UNRESOLVED |
| Evaluation of the effects of epigenetic and splicing inhibitors on viability and gene expression signatures of GBM PDOs and GSCs | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PDO arm
- description
- Tumor tissue from enrolled patients will be collected and used to generate PDOs.
- interventionNames
- Biological: Development and characterization of PDOs
- Biological: Evaluation of the effects of epigenetic and splicing inhibitors on viability and gene expression signatures of GBM PDOs and GSCs
Primary outcomes (1)
- measure
- Histopathological PDO and tumor evaluation
- timeFrame
- From enrollment to 36 months
- description
- The histopathological resemblance of PDOs to primary tumor will be rated semiquantitatively (0-10). The efficacy of treatment on PDOs will be rated using the % of dead cells.
Secondary outcomes (1)
- measure
- Histopatological primary and recurrent PDO evaluation.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * adult patients undergoing resective neurosurgery for glioblastoma, IDH-wildtype Exclusion Criteria: * Needle biopsies * Age \<18 years * Inability to give informed consent * Brain surgery for tumor disease other than GBM * Previous neoadjuvant chemotherapy or radiotherapy
References
Publications (0)
Data not yet available